Veligrotug is an intravenously administered anti-insulin-like growth factor-1 receptor antibody developed for the treatment of thyroid eye disease (TED). Veligrotug has demonstrated rapid reductions in diplopia as well as improvements in orbital inflammation, thereby highlighting its potential as a targeted biologic research tool in autoimmune ophthalmopathy.
Purity:
99.80%
CAS Number:
[2728655-31-8]
Target:
IGF-1R
* VAT and and shipping costs not included. Errors and price changes excepted
